IMPORTANT RAMQ PROGRAM INFORMATION DEXCOM G6 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM

Effective May 27, 2021, the Dexcom G6 Continuous Glucose Monitoring (CGM) System has been approved for reimbursement by the Régie de l'assurance maladie du Québec (RAMQ).

How do patients qualify?

To receive coverage for Dexcom G6, patients must meet the eligibility requirements for the Public Insurance Plan under RAMQ. In addition, they must be:

• Living with Type 1 diabetes and age 2 years or older.

AND, they must have one or more of the following:

- Failure to achieve an appropriate glycated hemoglobin (A1C) value despite taking prescribed medications and testing blood sugar regularly;
- Have experienced frequent episodes of hypoglycemia in the past year despite following a treatment plan;
- Inability to recognize or report symptoms of hypoglycemia.

For a complete description of coverage criteria, please visit: <u>https://www.ramq.gouv.qc.ca/en/about-us/list-medications</u>

How do patients get coverage?

Patients should first notify you or speak to you about a prescription for the Dexcom G6 CGM System. You may then take the following actions:

- 1. Complete an Exceptional Medication Form for the patient and submit it to RAMQ for pre-approval if they are covered under the program.
- 2. Provide the patient with a prescription for Dexcom G6.

What are the next steps for the patient?

Patients should then take their prescription to their local pharmacy. Their pharmacist will validate their RAMQ approval status, and then order their Dexcom G6 supplies.

How long will patients be covered for?

Once approved, the patient's initial request is valid for **six months**. After that time, you may reassess the patient and submit a request to continue treatment. Subsequent requests are authorized for 12 months at a time.

What if a patient has private insurance?

Private insurance plans must at least match the coverage for medications covered by RAMQ. Now that Dexcom G6 is part of this list of medications, patients should now qualify if they meet the eligibility requirements.

If a patient does not meet the criteria, their private plan may still offer coverage. We suggest the patient contacts their insurer for more details or speaks to their pharmacist about verifying their coverage.

Who do I contact if I have questions?

Healthcare professionals can find helpful information, resources and videos online at <u>ca.provider.dexcom.com</u>, or may contact us by toll-free phone at 1-844-536-8388 or by email at <u>ca.hcpsales@dexcom.com</u>.

Patients can find helpful information, resources and videos online at <u>Dexcom.com</u>, or may contact us by toll-free phone at 1-844-832-1810 or by email at <u>ca.sales@dexcom.com</u>.



THE POWER TO CHANGE HOW PATIENTS LIVE WITH DIABETES

Dexcom**G6**



Dexcom G6 measures glucose levels up to every five minutes using a sensor inserted just underneath the skin, and wirelessly transmits glucose readings to a receiver or compatible smart device.[‡]



Zero fingersticks* or scanning required No fingersticks* needed for treatment decisions or insulin dosing**



Dexcom CGM Lowers A1C^{1,3} Proven to reduce A1C and decrease risk of hypoglycemia for people using insulin^{1,3}



Custom alerts and alarm Customizable high and low glucose alerts, and an Urgent Low Soon alert that can proactively warn users if they will be $\leq 3.1 \text{ mmol/L}$ within 20 minutes.



Remote data sharing[†] Capability to share real-time glucose data with up to five loved ones



10-day sensor wear New, extended 10-day sensor wear



Increases time spent in range^{1,3} Dexcom CGM users spend more time in range than those using fingersticks

Reduces hypoglycemic events^{2,3}

of hypoglycemic events in people

with diabetes

Demonstrated to reduce the number



Pediatrics The only CGM approved for ages 2 years and up

For more info on Dexcom G6, visit us online: CA.PROVIDER.DEXCOM.COM

- * If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. ** When the sensor code is entered.
- † Internet connectivity required for data sharing. Following requires the use of the Follow App.
- For a list of compatible devices, visit <u>www.dexcom.com/compatibility</u>.
- 1 Beck R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Injections for Insulin Delivery: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.
- 2 Heinemann L, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe
- hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. The Lancet. 2018;391(10128): 1367-1377.
- 3 Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3).